A new company is responsible for Japanese promotional activities for Actair, Stallergenes Greer’s sublingual immunotherapy ...

Stallergenes Greer, Shionogi & Co., Ltd. ("Shionogi") and CEOLIA Pharma Co. Ltd ("CEOLIA") today announced the transition of promotional activities for Actair® in Japan. Actair® is Stallergenes ...

Stallergenes Greer, Shionogi Co., Ltd. ("Shionogi") and CEOLIA Pharma Co. Ltd ("CEOLIA") today announced the transition of promotional activities for Actair® in Japan. Actair® is Stallergenes Greer's ...

This Research Topic is the second volume of the “Exploring Immunological Tolerance in Allergy Treatment through AIT” Community Series. Please see Volume I ...

The FDA has accepted Aquestive Therapeutics’ new drug application for its Anaphylm sublingual epinephrine film for treating ...

Overall, 64.4% of patients treated with the sublingual tablets (vs. 54.7% in the placebo group) had good functional outcomes. The safety profile of Sanbexin was similar to that of the placebo (89. ...

While immunotherapy has transformed the treatment of many cancers, it has failed to make much of an impact in advanced ovarian cancer, and AstraZeneca is hoping to change that. At ASCO, AZ ...